Implant Or Insert Patents (Class 424/422)
  • Patent number: 11311643
    Abstract: Various compositions of matter, methods of making compositions of matter, and methods of using compositions of matter, e.g. for inducing hemostasis, are disclosed. In some embodiments, a starting fibrin material is subjected to controlled hydrolysis, desirably base-catalyzed, to prepare a fibrin hydrolysate material with increased water sorption capacity. Such fibrin hydrolysate materials, alone or combined with one or more additional substances, can be used in the preparation of hemostasis promoting foams, powders or gels. In some embodiments, a starting dialdehyde starch material is subjected to controlled hydrolysis to prepare a dialdehyde starch hydrolysate material. Such dialdehyde starch hydrolysate materials, alone or combined with one or more additional substances, in some cases combined with a fibrin hydrolysate material, can be used in the preparation of hemostasis promoting foams, powders or gels.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: April 26, 2022
    Assignee: Cook Biotech Incorporated
    Inventors: Niraj Ramachandran, Brooke Lynn Davisson
  • Patent number: 11291630
    Abstract: The present invention relates to gelling compositions, which changes from liquid state to gel state in function of temperature comprising: at least a poloxamer or mixture of poloxamers; at least a gelling agent; and at least an anticancer agent. Said compositions are advantageously used for local administration of an anticancer agent. Said compositions are useful for size-reduction of a tumour before surgical removal of said tumour, for preventing tumour recurrence after surgical removal of a tumour, and/or treating small tumours. They are therefore useful for the treatment of cancer, preferably a cancer of a wall of the digestive system or a gynaecologic cancer. The present invention also relates to a method for preparing said gelling compositions.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: April 5, 2022
    Inventors: Nathalie Mignet, Vincent Pierre-Marie Boudy, Johanne Seguin, Daniel Scherman, Yoran Beldengrun
  • Patent number: 11278493
    Abstract: This disclosure is directed to an ophthalmic formulation for dry eye and other ocular indications that provides long-lasting benefits. The formulations described herein provide durable relief and last two to ten longer on the eye than currently marketed products. The disclosure also provides methods of alleviating the symptoms of dry eye, methods for delivering ophthalmic pharmaceuticals, and methods of manufacture of the long-lasting ophthalmic formulations.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: March 22, 2022
    Assignee: ETERNATEAR, INC.
    Inventors: Timothy R. Willis, Ralph P. Stone
  • Patent number: 11267851
    Abstract: An antimicrobial adhesive protein, an antimicrobial nanoparticle, an antimicrobial composition comprising the same nanoparticle, and a preparation method for the same composition are described and, more particularly, an antimicrobial adhesive protein in which an antibiotic peptide is linked to a mussel adhesive protein, a mussel adhesive protein derivative of which a tyrosine residue within the antimicrobial adhesive protein is modified with a catechol derivative, an antimicrobial nanoparticle including a metal capable of forming a coordinate bond with a derivative of the mussel adhesive protein and having intrinsic antimicrobial activity, an antimicrobial composition comprising the same nanoparticle, and a preparation method for the same composition are described.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: March 8, 2022
    Assignees: POSCO, POSTECH ACADEMY-INDUSTRY FOUNDATION
    Inventors: Hyung Joon Cha, Yun Kee Jo, Yeonsu Jeong
  • Patent number: 11237991
    Abstract: A processing accelerator includes a shared memory, and a stream accelerator, a memory-to-memory accelerator, and a common DMA controller coupled to the shared memory. The stream accelerator is configured to process a real-time data stream, and to store stream accelerator output data generated by processing the real-time data stream in the shared memory. The memory-to-memory accelerator is configured to retrieve input data from the shared memory, to process the input data, and to store, in the shared memory, memory-to-memory accelerator output data generated by processing the input data. The common DMA controller is configured to retrieve stream accelerator output data from the shared memory and transfer the stream accelerator output data to memory external to the processing accelerator; and to retrieve the memory-to-memory accelerator output data from the shared memory and transfer the memory-to-memory accelerator output data to memory external to the processing accelerator.
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: February 1, 2022
    Assignee: TEXAS INSTRUMENTS INCORPORATED
    Inventors: Mihir Mody, Niraj Nandan, Hetul Sanghvi, Brian Chae, Rajasekhar Reddy Allu, Jason A. T. Jones, Anthony Lell, Anish Reghunath
  • Patent number: 11229607
    Abstract: The present invention provides injectable compositions comprising cells encapsulated in hydrogel capsules and methods of preparing these compositions. The present invention also provides methods for using these compositions to promote hematopoiesis and to treat or prevent cardiovascular and immunological disorders in a subject.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: January 25, 2022
    Assignee: President and Fellows of Harvard College
    Inventors: Jae-Won Shin, Angelo S. Mao, Stefanie Utech, David A. Weitz, David J. Mooney, Oktay Uzun
  • Patent number: 11229724
    Abstract: The invention relates to biocompatible, bioabsorbable derivatized non-crosslinked chitosan compositions optionally crosslinked to gelatin/collagen by 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) for biomedical use and methods of making and testing such compositions, including a modified acute systemic toxicity test. The compositions comprise derivatized chitosan reacetylated to a degree of N-deacetylation (DDA) of between about 15% and 40%. The compositions are typically bioabsorbed in about 90 days or less and can be made to bioabsorb at differing rates of speed. The compositions are initially soluble in aqueous solution below pH 6.5. The compositions have an acid content that can be adjusted between about 0% (w/w) and about 8% (w/w) to customize the composition for uses that require and/or tolerate differing levels of cytotoxicity, adhesion, composition cohesion, and cell infiltration into the composition.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: January 25, 2022
    Assignee: Tricol Biomedical, Inc.
    Inventors: Barbara McGrath, Simon McCarthy, Sam Kuhn, Alysha Wold, Michael Stolten, Amanda Bennett
  • Patent number: 11219706
    Abstract: Provided are formulations and related methods, for coating or impregnating a medical device, as well as a coated or impregnated medical device, for example, a device that is a catheter or cannula, where a different formulation may be used for interior surface of device and for exterior surface of the device.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: January 11, 2022
    Assignee: ARROW INTERNATIONAL LLC
    Inventors: Kamma Giare-Patel, Nisha Gupta, Greg Etter, Kevin Sechrist, Molly Stewart, Igor Tentler, Al Williams
  • Patent number: 11191868
    Abstract: The present patent application is directed to compositions and shaped structures implantable into mammalian bodies, the compositions and shaped structures having localized bioactive surfaces.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: December 7, 2021
    Assignee: SYNERGY BIOMEDICAL, LLC
    Inventor: Mark D. Borden
  • Patent number: 11185417
    Abstract: Method and set of surgical instruments for fitting a shoulder prosthesis, and the shoulder prosthesis. The proposed method seeks to interpose a bone graft between the previously prepared glenoid surface (G) of a scapula (S) of a patient's shoulder and the face of a glenoid prosthetic component opposite the articular surface. The set of instruments permit the bone graft to be taken from the upper epiphysis of the humerus (H), either in situ or ex vivo.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: November 30, 2021
    Assignee: TORNIER SAS
    Inventors: Pascal Boileau, Gilles Walch
  • Patent number: 11185616
    Abstract: Implantable medical product, comprising a basic body and an imidazole derivative in the form of its free base; wherein said basic body has on its polymeric surface a layer containing the imidazole derivative as an active ingredient, which displays an antithrombogenic, antiproliferative, anti-inflammatory or antiadhesive effect, or a combination thereof.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: November 30, 2021
    Inventor: Jörg Michael Schierholz
  • Patent number: 11160674
    Abstract: To provide a stent excellent in deformability, capable of maintaining a radial force for a longer period of time, and having bioabsorbability and a method of producing the same. The bioabsorbable stent has a core structure including a magnesium alloy and a corrosion resistant layer on the core structure, wherein the core structure is formed from a magnesium alloy containing 90 mass % or more of Mg as a main component, Zn, Zr, and Mn as accessory components, and 30 ppm or less of unavoidable impurities selected from the group consisting of Fe, Ni, Co, and Cu, and the alloy excluding aluminum and at least one sort of rare earths selected from the group consisting of Sc, Y, Dy, Sm, Ce, Gd, and La; and the corrosion resistant layer containing magnesium fluoride as a main component with a hydrophilic smooth surface is formed on the core structure with a smooth surface.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: November 2, 2021
    Assignees: Japan Medical Device Technology Co., LTD., FUJI LIGHT METAL CO., LTD.
    Inventors: Makoto Sasaki, Yuki Koga, Yuki Okazawa, Hironori Ueda, Masashi Inoue
  • Patent number: 11160902
    Abstract: An object of the invention is to provide a cartilage regenerative material that suppresses infiltration of fibrous soft tissue and brings about satisfactory cartilage regeneration, and a method for producing the cartilage regenerative material. Provided is a cartilage regenerative material including a porous body of a biocompatible polymer and a biocompatible polymer film, in which the porous body contains chondrocytes and cartilage matrix, and the cartilage matrix exists in a region of 10% or more of a region extending from the surface of the transplant face of the porous body to a depth of 150 ?m along the thickness.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: November 2, 2021
    Assignees: FUJIFILM Corporation, JAPAN TISSUE ENGINEERING CO., LTD.
    Inventors: Kentaro Nakamura, Hayato Miyoshi, Satoko Hada, Masatoki Watanabe
  • Patent number: 11154509
    Abstract: A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: October 26, 2021
    Assignees: EIRGEN PHARMA LTD., OPKO RENAL, LLC
    Inventors: Charles W. Bishop, Samir P. Tabash, Sammy A. Agudoawu, Jay A. White, Keith H. Crawford, Eric J. Messner, P. Martin Petkovich
  • Patent number: 11116872
    Abstract: A method of making infused bone fibers employs the following steps: cutting or shaving whole bone into bone fibers, washing the bone fibers, demineralizing or decalcifying at least partially the whole bone or bone fibers and infusing the bone fibers with a supernatant of biologic material or a polyampholyte cryoprotectant or a combination of both to create infused bone fibers. The step of infusing includes exposing the bone fibers to a negative pressure or vacuum to draw the supernatant and/or the polyampholyte cryoprotectant into the bone fibers, or alternatively, exposing the demineralized whole bone to a positive pressure to drive the supernatant and/or the polyampholyte cryoprotectant into the bone. The resultant method creates an infused bone grafting composition having bone fibers taken from whole bone, demineralized or decalcified at least partially and infused with one or more of a supernatant of biologic material or a polyampholyte cryoprotectant or both.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: September 14, 2021
    Assignee: Vivex Biologies Group, Inc.
    Inventors: Timothy Ganey, Tracy Scott Anderson, Harry Thomas Temple
  • Patent number: 11116870
    Abstract: Compositions and blends of biopolymers and copolymers are described, along with their use to prepare biocompatible scaffolds and surgically implantable devices for use in supporting and facilitating the repair of soft tissue injuries.
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: September 14, 2021
    Assignee: EMBODY INC.
    Inventors: Michael Francis, Nathan Kemper, Hilary Wriggers
  • Patent number: 11103723
    Abstract: Provided herein are methods for the treatment of bladder dysfunction, including detrusor hyperreflexia and detrusor external sphincter dyssynergia, fecal incontinence, and/or sexual dysfunction in an individual via the use of stably expressed light-responsive opsin proteins capable of selective hyperpolarization or depolarization of the neural cells that innervate the muscles responsible for physiologic functioning of urinary bladder, external urinary sphincter, external anal sphincter, and the male and female genitalia.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: August 31, 2021
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Circuit Therapeutics, Inc.
    Inventors: Karl A. Deisseroth, Elizabeth R. Aden, Viviana Gradinaru, Scott L. Delp
  • Patent number: 11097007
    Abstract: An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 s?1 and having a viscosity of 0.2 pascal-seconds or less in at least one point in the shear rate range of 900 to 1,000 s?1, as measured.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: August 24, 2021
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Daiki Kaneko, Takakuni Matsuda, Yusuke Hoshika
  • Patent number: 11096888
    Abstract: The invention relates to a method for altering the release characteristics of a long acting drug delivery device containing at least two drugs in different segments, wherein the segments are arranged to a specific sequence. The invention furthermore relates to a drug delivery device with reduced initial burst containing two different drugs in different segments. The invention further relates to a delivery device manufactured according to the a.m. method and its use in contraception and gynecological therapies.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: August 24, 2021
    Assignee: Bayer OY
    Inventors: Savante Holmberg, Christine Talling
  • Patent number: 11090411
    Abstract: A method of making an electron beam irradiated osteoinductive implant is provided. The method comprises exposing an osteoinductive implant containing demineralized bone matrix (DBM) fibers to electron beam radiation at a dose of from about 10 kilograys to 100 kilograys for a period of time. The electron beam irradiation reduces microorganisms in the osteoinductive implant, and the electron beam irradiated osteoinductive implant retains osteoinductive properties. Methods of implantation and an irradiated osteoinductive implant are also disclosed.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: August 17, 2021
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Kelly W. Schlachter, Erick Vasquez, Daniel A. Shimko
  • Patent number: 11058734
    Abstract: The invention relates to a probiotic strain selected from Lactobacillus reuteri V340 with accession number CECT and Bifidobacterium breve BT820 with accession number CECT 8606, or a variant of said probiotic strain having cholesterol-absorbing capacity, and to methods and therapeutic uses thereof. The invention also relates to compositions, pharmaceutical compositions, feeds or nutritional products comprising a probiotic strain selected from Lactobacillus reuteri V3401 with accession number CECT 8605 and Bifidobacterium breve BT820 with accession number CECT 8606, or a variant of said probiotic strain having cholesterol-absorbing capacity.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: July 13, 2021
    Assignee: BIOSEARCH, S.A.
    Inventors: Ana Isabel Sañudo Otero, Raquel Criado García, Alba Rodríguez Nogales, Alberto Garach Domech, Mónica Olivares Martín, Julio Juan Gálvez Peralta, Santiago De La Escalera Huerso, Juan Manuel Duarte Pérez, Antonio Zarzuelo Zurita, Óscar Bañuelos Hortigüela
  • Patent number: 11051543
    Abstract: An ingestible compositions includes a first polymer layer, an adhesive layer associated with the first polymer layer, where the adhesive layer includes an adhesive material and is configured to releasably adhere to the first polymer layer, an alginate layer adhered to the adhesive layer, and a second polymer layer associated with the alginate layer and configured to releasably adhere to the alginate layer. Aspects further include methods of making and using the compositions.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: July 6, 2021
    Assignee: OTSUKA PHARMACEUTICAL CO. LTD.
    Inventors: Raymond Schmidt, Hooman Hafezi, Ai Ling Ching, Patricia Johnson, Anuj Patel, Kevin Cheng, Kosuke Iwai
  • Patent number: 11027040
    Abstract: The present disclosure provides a method for manufacturing a porous film, including: preparing a polymer mixture solution, wherein the polymer mixture solution includes polycaprolactone and at least one hydrophobic polymer; adding solid particles as a dispersing agent to the polymer mixture solution and mixing the solid particles with the polymer mixture solution, wherein the amount of solid particles added is enough to convert the polymer mixture solution into a solid mixture; drying the solid mixture to form a film; and washing the film with a washing fluid to remove the solid particles from the film to form the porous film, wherein the weight ratio of the polycaprolactone to the at least one hydrophobic polymer is about 1:0.1-10, and wherein the weight ratio of the polycaprolactone and the at least one hydrophobic polymer to the solid particles is about 1:0.01-250.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: June 8, 2021
    Assignee: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Hsin-Hsin Shen, Ming-Chia Yang, Chia-Chi Ho, Fang-Jie Jang, Che-Yu Ou, Chi-Hsiang Liao, Brian Hsu, Tai-Horng Young
  • Patent number: 11020116
    Abstract: Various exemplary surgical adjuncts with medicants affected by activator materials are provided. In general, an adjunct is provided with at least one medicant that is configured to be activated by an activator material. The adjunct can be delivered to a tissue of a patient, where the adjunct can be implanted. Various activator materials can be configured to activate the at least one medicant retained by the adjunct, the activation causing any one or more of a variety of actions. For example, the at least one medicant can be activated so as to yield at least one of a signal and/or an effect on the adjunct.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: June 1, 2021
    Assignee: Ethicon LLC
    Inventors: Frederick E. Shelton, IV, Jason L. Harris
  • Patent number: 11007278
    Abstract: Embodiments of the present disclosure provide for electroactive supramolecular polymeric assemblies, methods of making electroactive supramolecular polymeric assemblies, methods of using electroactive supramolecular polymeric assemblies, and the like.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: May 18, 2021
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: John Hardy, Christine E. Schmidt
  • Patent number: 11000627
    Abstract: The present invention relates to a process of treating an implant, comprising a step of treating the surface of the implant with at least one phosphonic acid compound or a pharmaceutically acceptable salt, ester or amide thereof under sonication at a temperature of about 50° C. to about 90° C. This process is highly advantageous in that it allows the formation of a monolayer of the phosphonic acid compound on the implant surface, having a particularly dense surface coverage which, in turn, results in an improved implant biocompatibility and improved osseointegration.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: May 11, 2021
    Assignee: NANO BRIDGING MOLECULES SA
    Inventors: Sabrina Buchini, Richard Curno, Björn-Owe Aronsson, Péter Péchy
  • Patent number: 10993919
    Abstract: Compositions and methods are disclosed herein to deliver and anchor nanoscale drug carriers into the extracellular matrix (ECM) of tissues, such as degenerating cartilage or tumor margins, and to provide local and sustained release of drugs.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: May 4, 2021
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Blanka Sharma, Shannon B. Brown
  • Patent number: 10961501
    Abstract: A system for seeding therapeutic active ingredients (TAIs) onto a porous scaffold includes a first chamber for accommodating the scaffold, a TAI storage device for storing TAIs, at least one second chamber for storing TAI media, and a gas inlet for receiving gas from a compressed source. A flow circuit is coupled to the first chamber, the TAI storage device, the second chamber and the gas inlet for delivering the TAIs, the TAI media and the gas to the scaffold. A pump pumps at least one of the TAIs, the TAI media and the gas in the flow circuit. The system also includes a processor that regulates the delivery of the TAIs, the TAI media and the gas to the scaffold via a plurality of valves.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: March 30, 2021
    Assignee: EpiBone, Inc.
    Inventors: Sarindr Bhumiratana, Keith Yeager
  • Patent number: 10953135
    Abstract: Disclosed herein are tissue scaffold materials with microspheres of one density embedded in hydrogel of a different density. The disclosed materials have improved ability to facilitate cellular invasion and vascularization for wound healing and tissue regeneration. The inventors have found that materials having components with different densities promotes invasion of cells, including desirable cells such as fibroblasts and endothelial precursor cells, into the scaffold.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: March 23, 2021
    Assignee: Cornell University
    Inventors: Jason Spector, Abraham D. Stroock, John Morgan
  • Patent number: 10945997
    Abstract: An object of the invention is to obtain a preparation which shows enhanced effectiveness and safety compared to tacrolimus, has the concentration in blood maintained at a constant level without individual differences, whereby the control of the amount of administration depending on the blood kinetics (blood trough concentration) becomes unnecessary. The present invention relates to a polymeric derivative of tacrolimus, in which a polyethylene glycol segment and an alcoholic hydroxy group of tacrolimus are bonded to side-chain carboxy groups of a polyaspartic acid derivative.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: March 16, 2021
    Assignee: Nippon Kayaku Kabushiki Kaisha
    Inventors: Nao Yoneki, Akihiro Sekiguchi, Kana Mizunuma, Yuki Kobayashi, Junpei Konno, Kan Saiga, Keiichirou Yamamoto
  • Patent number: 10947282
    Abstract: Embodiments of the invention are directed to Ubx-fusion molecules that maintain their mechanical strength and properties even after being fused with Ubx. Ubx fusions with VEGF and other growth factors, cell signaling proteins, and cell binding proteins can be used to induce angiogenesis. Ubx fibers and mesh, embedded within a tissue engineering scaffold, induce formation of vasculature within the scaffold. The presence of vasculature is necessary to provide oxygen and nutrients to other cells growing within the scaffold.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: March 16, 2021
    Assignees: The Texas A & M University System, William Marsh Rice University
    Inventors: Sarah Bondos, Kayla Bayless, Kathleen Matthews, Jan Patterson, Colette Abbey, David Howell, Hao-Ching Hsiao, Kelly Churion, Shang-Pu Tsai, Sandhya Ramasamy, Dustin Porterpan, Keira Northern
  • Patent number: 10940157
    Abstract: The present disclosure relates to a vaginal system that prevents pregnancy comprised of segesterone acetate and ethinyl estradiol and is configured for thirteen 28-day product-use cycles.
    Type: Grant
    Filed: March 10, 2020
    Date of Patent: March 9, 2021
    Assignee: The Population Council, Inc.
    Inventor: Bruce Variano
  • Patent number: 10933174
    Abstract: An anchorage device is provided that is configured to surround an implantable medical device. The anchorage device includes a substrate having a hemostatic agent and an active pharmaceutical ingredient selectively positioned on the substrate. Kits, systems and methods are disclosed.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: March 2, 2021
    Assignee: MEDTRONIC, INC.
    Inventors: Satish Pulapura, Fatima Buevich, Jorie S. Soskin, Franklin R. Mansfield, Kai R. Worrell, Charlie Wood, Jorge Alberto Trevino Blanco
  • Patent number: 10932465
    Abstract: The invention relates to an antimicrobial mixture containing 4-(3-ethoxy-4-hydroxy-phenyl)butan-2-one and an additional compound chosen from chlorhexidine digluconate, chlorhexidine hydrochloride and a polyhexamethylene biguanide salt, and also to a cosmetic composition containing such a mixture. Use in caring for, making up and cleansing keratin materials.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: March 2, 2021
    Assignee: L'OREAL
    Inventors: Julien Galvan, Sylvie Cupferman, Gael Malet
  • Patent number: 10925882
    Abstract: The present disclosure relates to a vaginal system that prevents pregnancy comprised of segesterone acetate and ethinyl estradiol and is configured for thirteen 28-day product-use cycles.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: February 23, 2021
    Assignee: The Population Council, Inc.
    Inventor: Bruce Variano
  • Patent number: 10918649
    Abstract: The present disclosure relates to a vaginal system that prevents pregnancy comprised of segesterone acetate and ethinyl estradiol and is configured for thirteen 28-day product-use cycles.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: February 16, 2021
    Assignee: The Population Council, Inc.
    Inventor: Bruce Variano
  • Patent number: 10881537
    Abstract: The present invention relates generally a manufacturing process which results in a completely hydrogel polymer device that maintains lumen patency which allows for numerous applications. Catheters and stents are particular examples, and their composition, mechanical characteristics, and the significantly unique ability to conduct and allow fluids to pass from one end to the other without physiological rejection, inflammation, or manifestation of complications due to implant or otherwise undesirable outcomes when used for ambulatory and or therapeutic interventions is the purpose of the invention.
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: January 5, 2021
    Inventor: Scott M. Epstein
  • Patent number: 10881622
    Abstract: Technologies are described for delivery of compounds to aid in weight management. A transdermal microdispenser based system may deliver weight management compounds through the time and dose specific administration of appetite suppression, metabolic enhancers, and satiation compounds. The transdermal delivery system may be controlled based on data associated with subject such as calorie intake, physical activity, satiation, and hunger. The system may be integrated with medical monitoring or fitness tracking systems. Delivery of the compounds may be distributed over the course of a day at selected or adjusted doses to be safe and effective for their specific modality. For example, appetite suppressants may be delivered during periods of the day when cravings occur, satiation compounds may be delivered to coincide with meals, and metabolic stimulators may be delivered at times to optimally increase metabolism based on caloric balance. Control factors may also be predictive to prevent the onset of hunger.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: January 5, 2021
    Assignee: Xinova, LLC
    Inventors: Michael Keoni Manion, Stephanie Brunelle
  • Patent number: 10881619
    Abstract: In one aspect, the present disclosure provides microparticles that are configured to release a first drug over a first time period and to release a second drug over a second time period, wherein a lag period of substantially no drug release occurs between the first and second time periods. In other aspects, the present disclosure pertains to the use of such microparticles in delivery systems and methods of treatment. In another aspect, the present disclosure pertains to drug delivery systems that comprising a folded inflatable drug delivery balloon that comprises folds and microparticles positioned within the folds.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: January 5, 2021
    Assignee: Boston Scientific Scimed, Inc.
    Inventors: Javier Palomar-Moreno, Michelle Hannon, Phillip Bannister
  • Patent number: 10881695
    Abstract: An autologous cell therapy product composed of fibroblasts grown for each individual to be treated for vocal cord scarring. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own buccal mucosa or skin using current good manufacturing practices (CGMP) and standard tissue culture procedures, is supplied in cryovials containing cryopreserved autologous fibroblasts or precursors thereof, at a concentration of between 1.0×107 cells/mL and 2.7×107 cells/mL, wherein at least 85% of the human fibroblast cells are viable after freezing and thawing.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: January 5, 2021
    Assignee: Fibrocell Technologies, Inc.
    Inventor: John Maslowski
  • Patent number: 10881501
    Abstract: Allografts for soft tissue repair, including breast reconstruction and other plastic surgery procedures, are disclosed. One allograft is made from decellularized dermal tissue and constitutes a collagen matrix having substantially uniform density and porosity. Another allograft is a hybrid bilayer tissue form that is made from decellularized dermal and adipose tissues. Methods for making both allografts are also disclosed.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: January 5, 2021
    Assignee: Musculoskeletal Transplant Foundation
    Inventors: Michael Locarno, Bryan Choi, Manh-Dan Ngo
  • Patent number: 10874108
    Abstract: A metal-EDTA compound/complex for combatting biofilms and/or treating wounds. The compound/complex comprises EDTA and from two to four metal ions. Of those two to four metal ions, at least two are different metal ions selected from Ag, Al, Au, Ba, Bi, Tl, Ce, Co, Cu, Fe, Ga, Ir, Mo, Rh, Ru, Ti, and Zn ions. The metal-EDTA compound/complex may exhibit any one or more of anti-microbial, anti-biofilm and anti-inflammatory activities in use and may increase the susceptibility of a biofilm and the microorganisms within said biofilm to attack by anti-microbial agents, helping to remove and sanitise the biofilm. A composition, wound dressing and medical device comprising the metal-EDTA complex are also provided. Uses of the metal-EDTA compound/complex as a medicament and/or to sanitise and/or substantially remove a biofilm from a substrate are also disclosed.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: December 29, 2020
    Assignee: 5D Health Protection Group Ltd.
    Inventors: Steven Percival, Rui Chen, John Alan Hunt
  • Patent number: 10869948
    Abstract: Disclosed is a composition of a collagen peptide and an elastin peptide, method of producing the same and use thereof. The composition of the present disclosure consists of a collagen peptide and an elastin peptide; the collagen peptide is prepared by enzymatic hydrolysis of a collagen material with pepsin or trypsin, and the elastin peptide is prepared by enzymatic hydrolysis of an elastin material with papain and/or protease Protamex. In the present disclosure, an elastin peptide and a collagen peptide with molecular weight in a specific range are prepared by specific processes, and the composition composed of the two at a suitable ratio can simultaneously and significantly increase the amount of the elastin and collagen in a damaged skin in a small usage amount, and significantly increase the content of hyaluronic acid and hydroxyproline while decrease the content of MMP3, meanwhile, inhibit skin inflammatory factors.
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: December 22, 2020
    Assignee: INFINITUS (CHINA) COMPANY LTD.
    Inventors: Huawei Zhu, Xiaoling Wang, Liugang Ding, Xiaolei Guo, Yazhong Ge
  • Patent number: 10869947
    Abstract: Hydrogel compositions are provided (a) that have a continuous hydrophobic phase and a discontinuous hydrophilic phase, (b) that have a discontinuous hydrophilic phase and a continuous hydrophilic phase, or (c) that are entirely composed of a continuous hydrophilic phase. The hydrophobic phase, if present, is composed of a hydrophobic polymer, particularly a hydrophobic pressure-sensitive adhesive (PSA), a plasticizing elastomer, a tackifying resin, and an optional antioxidant. The discontinuous hydrophilic phase, if present, is composed of a crosslinked hydrophilic polymer, particularly a crosslinked cellulosic polymer such as crosslinked sodium carboxymethylcellulose. For those hydrogel compositions containing a continuous hydrophilic phase, the components of the phase include a cellulose ester composition or an acrylate polymer or copolymer, and a blend of a hydrophilic polymer and a complementary oligomer capable of hydrogen bonding thereto.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: December 22, 2020
    Assignees: Corium, Inc., A.V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences
    Inventors: Gary W. Cleary, Shoreh Parandoosh, Mikhail M. Feldstein, Anatoly E. Chalykh, Nicolai A. Platè, Valery G. Kulichikhin
  • Patent number: 10864304
    Abstract: A material including a plurality of fatty acid chains cross-linked together and a silver fatty acid salt formed with the fatty acid chains within the material. Methods for forming a material are also included. The silver-containing materials can be utilized alone or in combination with a medical device for the release and local delivery of one or more anti-infective agents.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: December 15, 2020
    Assignee: ATRIUM MEDICAL CORPORATION
    Inventors: Keith M. Faucher, Hilda N. Rono, Anthony Richard Horton, Jocelyn Choroszy, Paul Martakos
  • Patent number: 10842913
    Abstract: Tissue repair and restoration can be performed using an elastic material formed from tropoelastin. The elastic material can be formed by providing a solution of tropoelastin monomers, applying the solution to a surface, and heating the solution on the surface in absence of a cross-linking agent to enable the tropoelastin monomers to bind to each other to form an elastic material that does not dissociate into tropoelastin monomers when the elastic material is contacted with an aqueous solution.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: November 24, 2020
    Assignee: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
    Inventors: Anthony Steven Weiss, Suzanne Marie Mithieux
  • Patent number: 10847363
    Abstract: Methods are provided for selective film deposition. One method includes providing a substrate containing a dielectric material and a metal layer, the metal layer having an oxidized metal layer thereon, coating the substrate with a metal-containing catalyst layer, treating the substrate with an alcohol solution that removes the oxidized metal layer from the metal layer along with the metal-containing catalyst layer on the oxidized metal layer, and exposing the substrate to a process gas containing a silanol gas for a time period that selectively deposits a SiO2 film on the metal-containing catalyst layer on the dielectric material.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: November 24, 2020
    Assignee: Tokyo Electron Limited
    Inventor: Kandabara Tapily
  • Patent number: 10821182
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: November 3, 2020
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Patent number: 10813763
    Abstract: An implantable mesh including demineralized bone fibers mechanically entangled into a biodegradable or permanent implantable mesh is provided. A method of preparing the implantable mesh is also provided. The method of preparing the implantable mesh includes mechanically entangling demineralized bone fibers with non-bone fibers to form the implantable mesh. The mechanical entanglement of the bone fibers into the implantable mesh is achieved by applying needle punching with barbed needles, spun lacing, entanglement with water jets or air jets or ultrasonic entanglement with ultrasonic waves. A method of implanting an implantable mesh at a target bone tissue site is also provided.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: October 27, 2020
    Assignee: Warsaw Orthopedic, Inc.
    Inventor: Kelly W. Schlachter
  • Patent number: 10799611
    Abstract: The present invention relates to a dry composition, which upon addition of an aqueous medium forms a substantially homogenous paste suitable for use in haemostasis procedures. The paste forms spontaneously upon addition of the liquid, hence no mechanical mixing is required for said paste to form. The invention further relates to methods of preparing said dry composition, a paste made from said dry composition and use of said paste for medical and surgical purposes.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: October 13, 2020
    Assignee: Ferrosan Medical Devices A/S
    Inventor: Kristian Larsen